Why BMEA fell 30.1% on Oct 14 2026: phase 1 results

THE SESSION

• 09:30 ETOpened at $0.9987, -20.7% on the previous close of $1.26
• 09:30 ETRegular-session high, $0.9987
• 12:37 ETRegular-session low, $0.8005
• 15:59 ETLast trade of the regular session, $0.8344, -33.8% on the previous close of $1.26
• Volume: 10.1M shares in regular hours, 1.3M before the open

BMEA opened at $0.9987, already 20.7% below the previous close, after preliminary Phase 1 results for oral GLP-1 candidate BMF-650 showed modest 1.5%-3.2% weight loss in most cohorts, while the 6.1% result came from a small, separately interpreted cohort. TapeRank read the clinical update as explaining the decline, and by 09:37 the stock ranked third at $0.8811, down 30.1%; it then fell to $0.8005 at 12:37 before recovering to finish at $0.8344, still 33.8% below the previous close. No halts were recorded.

WRITTEN THU OCT 15 2026 18:05 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

• 08:51 ETCitizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price TargetBenzinga
• 06:21 ETHC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price TargetBenzinga
• 02:12 ETWhat’s Going On With Biomea Fusion (BMEA) Stock After Hours?Benzinga
• TUE 17:35 ET8-K — Regulation FD Disclosure; Other Events; Financial Statements and ExhibitsSEC 8-K
• TUE 16:29 ETBiomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still OutstandingBenzinga
• TUE 16:10 ETBiomea Fusion Reports Phase 1 Results For Oral GLP-1 Candidate BMF-650, Showing Consistent Weight Reduction And Encouraging TolerabilityBenzinga